
Volitionrx Limited (VNRX) Stock Forecast & Price Target
Volitionrx Limited (VNRX) Analyst Ratings
Bulls say
VolitionRX Ltd. has achieved significant milestones in its commercialization efforts, including recording its first revenue from CE-Marked Nu.Q NETs automated assay sales and expanding evaluations to over 20 hospitals across 10 countries. The company has established key partnerships for human diagnostics, notably with Werfen and Hologic, bolstering its market presence and potential for broader oncology applications. Additionally, advancements in technology and a strong foothold in both human and veterinary diagnostics highlight VolitionRX's strategic position for future growth and increased healthcare utilization efficiency.
Bears say
VolitionRX Ltd faces significant dilution risk that negatively impacts its financial outlook, compelling a reduction in its valuation from $5.00 to $3.00. This dilution risk suggests potential challenges in raising sufficient capital without adversely affecting shareholder value. Consequently, the company's ability to sustain its growth trajectory and fund ongoing development of its diagnostic platform may be hindered, raising concerns among investors.
This aggregate rating is based on analysts' research of Volitionrx Limited and is not a guaranteed prediction by Public.com or investment advice.
Volitionrx Limited (VNRX) Analyst Forecast & Price Prediction
Start investing in Volitionrx Limited (VNRX)
Order type
Buy in
Order amount
Est. shares
0 shares